Industry & Policy News

[4D Molecular Therapeutics] 4D Molecular Therapeutics announced a strategic partnership focused on advancing new AAV-based gene-editing therapies for central nervous system (CNS) diseases with high unmet medical needs in both rare and common disease populations.

[Tango Therapeutics, Inc.] Tango Therapeutics, Inc. announced that the first patient has been dosed in the Phase I/II trial evaluating TNG348 as a single agent and in combination with olaparib, a PARP inhibitor, in patients with BRCA1/2-mutant or other HRD+ cancers. TNG348 is a novel, selective inhibitor of USP1.

[Galecto, Inc.] Galecto, Inc. announced positive topline results from a Phase IIa trial of GB2064 for the treatment of myelofibrosis. The MYLOX-1 trial dosed a total of 18 myelofibrosis patients, of which 11 patients had previously received janus kinase inhibitor (JAKi) therapy with ruxolitinib, with eight of those patients being refractory and three being intolerant to JAKi therapy.

[Sanara Medtech, Inc.] Sanara MedTech Inc. announced that it has signed an exclusive license agreement with Tufts University to develop and commercialize patented technology covering 18 unique collagen peptides.

[ISS National Lab] Dozens of science and technology development payloads returned to Earth from the ISS as SpaceX’s 29th Commercial Resupply Services (CRS) mission, contracted by NASA, successfully concluded. An investigation from the University of California, San Francisco that was funded by the U.S. National Science Foundation focused on aging and liver regeneration.

[Nature Reviews Drug Discovery] The FDA could soon approve Iovance’s lifileucel for advanced melanoma, a much-anticipated milestone for the 35-year-old T cell therapy modality.